Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer

Krishna Sharan, Donald Fernandes, P. Prakash Saxena, Sourjya Banerjee, Brijesh Sathian

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims and Objectives: To report the results of treatment with intraluminal brachytherapy (ILRT) after concurrent chemoradiotherapy for esophageal carcinoma with respect to disease free survival (DFS), dysphagia free interval (DFI), and complications of treatment. Materials and Methods: The study retrospectively analyzed the records of 26 eligible patients with nonmetastatic carcinoma of the esophagus treated with definitive chemoradiotherapy followed by ILRT between 2008 and 2011. The DFS and DFI were estimated and factors likely to influence them were analyzed. Results: Nineteen (73%) patients were males. The mean age at presentation was 60 years (range: 47-90 years). All the patients had squamous cell carcinomas. Following treatment, the median DFS was 12.7 months (range: 0-27 months). Sixteen patients (61.5%) had local control of their disease, while one had residual disease at completion of treatment. Other than three patients who were not evaluated for recurrent dysphagia, six (23.1%) had proven local recurrence on follow-up. The estimated mean DFI was 13.8 months (range: 0-27 months). One patient died of tracheoesophageal fistula following treatment. On statistical analysis, only the location of tumor was prognostically significant, with lower third tumors performing worse. Other probable predictors of poor outcome included large volume (> 40 cc), tumor length (> 6 cm), and eccentric location. Conclusion: ILRT boost following concurrent chemoradiotherapy is well tolerated and potentially improves outcomes. It might be beneficial in selected patients with esophageal carcinoma. Further studies are required to identify its role in definitive treatment.

Original languageEnglish
Pages (from-to)337-341
Number of pages5
JournalJournal of Cancer Research and Therapeutics
Volume10
Issue number2
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

Brachytherapy
Chemoradiotherapy
Esophageal Neoplasms
Deglutition Disorders
Disease-Free Survival
Carcinoma
Therapeutics
Tracheoesophageal Fistula
Neoplasms
Esophagus
Squamous Cell Carcinoma
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Sharan, Krishna ; Fernandes, Donald ; Prakash Saxena, P. ; Banerjee, Sourjya ; Sathian, Brijesh. / Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer. In: Journal of Cancer Research and Therapeutics. 2014 ; Vol. 10, No. 2. pp. 337-341.
@article{3d16f3353aee46aeb16fd711911a3e62,
title = "Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer",
abstract = "Aims and Objectives: To report the results of treatment with intraluminal brachytherapy (ILRT) after concurrent chemoradiotherapy for esophageal carcinoma with respect to disease free survival (DFS), dysphagia free interval (DFI), and complications of treatment. Materials and Methods: The study retrospectively analyzed the records of 26 eligible patients with nonmetastatic carcinoma of the esophagus treated with definitive chemoradiotherapy followed by ILRT between 2008 and 2011. The DFS and DFI were estimated and factors likely to influence them were analyzed. Results: Nineteen (73{\%}) patients were males. The mean age at presentation was 60 years (range: 47-90 years). All the patients had squamous cell carcinomas. Following treatment, the median DFS was 12.7 months (range: 0-27 months). Sixteen patients (61.5{\%}) had local control of their disease, while one had residual disease at completion of treatment. Other than three patients who were not evaluated for recurrent dysphagia, six (23.1{\%}) had proven local recurrence on follow-up. The estimated mean DFI was 13.8 months (range: 0-27 months). One patient died of tracheoesophageal fistula following treatment. On statistical analysis, only the location of tumor was prognostically significant, with lower third tumors performing worse. Other probable predictors of poor outcome included large volume (> 40 cc), tumor length (> 6 cm), and eccentric location. Conclusion: ILRT boost following concurrent chemoradiotherapy is well tolerated and potentially improves outcomes. It might be beneficial in selected patients with esophageal carcinoma. Further studies are required to identify its role in definitive treatment.",
author = "Krishna Sharan and Donald Fernandes and {Prakash Saxena}, P. and Sourjya Banerjee and Brijesh Sathian",
year = "2014",
month = "1",
day = "1",
doi = "10.4103/0973-1482.136623",
language = "English",
volume = "10",
pages = "337--341",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer. / Sharan, Krishna; Fernandes, Donald; Prakash Saxena, P.; Banerjee, Sourjya; Sathian, Brijesh.

In: Journal of Cancer Research and Therapeutics, Vol. 10, No. 2, 01.01.2014, p. 337-341.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer

AU - Sharan, Krishna

AU - Fernandes, Donald

AU - Prakash Saxena, P.

AU - Banerjee, Sourjya

AU - Sathian, Brijesh

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aims and Objectives: To report the results of treatment with intraluminal brachytherapy (ILRT) after concurrent chemoradiotherapy for esophageal carcinoma with respect to disease free survival (DFS), dysphagia free interval (DFI), and complications of treatment. Materials and Methods: The study retrospectively analyzed the records of 26 eligible patients with nonmetastatic carcinoma of the esophagus treated with definitive chemoradiotherapy followed by ILRT between 2008 and 2011. The DFS and DFI were estimated and factors likely to influence them were analyzed. Results: Nineteen (73%) patients were males. The mean age at presentation was 60 years (range: 47-90 years). All the patients had squamous cell carcinomas. Following treatment, the median DFS was 12.7 months (range: 0-27 months). Sixteen patients (61.5%) had local control of their disease, while one had residual disease at completion of treatment. Other than three patients who were not evaluated for recurrent dysphagia, six (23.1%) had proven local recurrence on follow-up. The estimated mean DFI was 13.8 months (range: 0-27 months). One patient died of tracheoesophageal fistula following treatment. On statistical analysis, only the location of tumor was prognostically significant, with lower third tumors performing worse. Other probable predictors of poor outcome included large volume (> 40 cc), tumor length (> 6 cm), and eccentric location. Conclusion: ILRT boost following concurrent chemoradiotherapy is well tolerated and potentially improves outcomes. It might be beneficial in selected patients with esophageal carcinoma. Further studies are required to identify its role in definitive treatment.

AB - Aims and Objectives: To report the results of treatment with intraluminal brachytherapy (ILRT) after concurrent chemoradiotherapy for esophageal carcinoma with respect to disease free survival (DFS), dysphagia free interval (DFI), and complications of treatment. Materials and Methods: The study retrospectively analyzed the records of 26 eligible patients with nonmetastatic carcinoma of the esophagus treated with definitive chemoradiotherapy followed by ILRT between 2008 and 2011. The DFS and DFI were estimated and factors likely to influence them were analyzed. Results: Nineteen (73%) patients were males. The mean age at presentation was 60 years (range: 47-90 years). All the patients had squamous cell carcinomas. Following treatment, the median DFS was 12.7 months (range: 0-27 months). Sixteen patients (61.5%) had local control of their disease, while one had residual disease at completion of treatment. Other than three patients who were not evaluated for recurrent dysphagia, six (23.1%) had proven local recurrence on follow-up. The estimated mean DFI was 13.8 months (range: 0-27 months). One patient died of tracheoesophageal fistula following treatment. On statistical analysis, only the location of tumor was prognostically significant, with lower third tumors performing worse. Other probable predictors of poor outcome included large volume (> 40 cc), tumor length (> 6 cm), and eccentric location. Conclusion: ILRT boost following concurrent chemoradiotherapy is well tolerated and potentially improves outcomes. It might be beneficial in selected patients with esophageal carcinoma. Further studies are required to identify its role in definitive treatment.

UR - http://www.scopus.com/inward/record.url?scp=84905709025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905709025&partnerID=8YFLogxK

U2 - 10.4103/0973-1482.136623

DO - 10.4103/0973-1482.136623

M3 - Article

VL - 10

SP - 337

EP - 341

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

IS - 2

ER -